AURA David Michael Johnson buys $0 worth of shares
May 21, 2025, 4:38 AM
0.00%
What does AURA do
Aura Biosciences, a clinical-stage oncology company based in Boston, develops virus-like drug conjugates (VDCs) to selectively target cancer cells and activate immune responses. Its lead candidate, bel-sar, is in late-stage clinical development for choroidal melanoma and bladder cancer.
David Michael Johnson bought 25,000 shares of AURA on 16 May at $0.00 per share, worth a total of $0. They now own 166,167 AURA shares, or a 18% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.